Equities

Mevis Medical Solutions AG

Mevis Medical Solutions AG

Actions
  • Price (EUR)24.00
  • Today's Change0.00 / 0.00%
  • Shares traded25.00
  • 1 Year change-5.51%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments7.749.327.62
Total Receivables, Net3.274.742.80
Total Inventory------
Prepaid expenses0.050.130.10
Other current assets, total0.310.310.35
Total current assets111511
Property, plant & equipment, net0.150.160.12
Goodwill, net------
Intangibles, net00.000.00
Long term investments0.310.310.31
Note receivable - long term161616
Other long term assets------
Total assets283128
LIABILITIES
Accounts payable0.080.190.24
Accrued expenses0.040.030.03
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total6.749.456.42
Total current liabilities6.859.676.69
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total3.383.703.01
Total liabilities10139.71
SHAREHOLDERS EQUITY
Common stock1.821.821.82
Additional paid-in capital111111
Retained earnings (accumulated deficit)4.544.544.54
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity181818
Total liabilities & shareholders' equity283128
Total common shares outstanding1.821.821.82
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.